Sanofi operating income up 16% on bestseller drug Dupixent
28/04/2022 06:30
April 28 (Reuters) - French healthcare group Sanofi's
SASY.PA first quarter adjusted earnings gained 16.2% on
continued sales growth of its bestselling drug Dupixent.
First-quarter business operating income, or adjusted
earnings before interest and tax, rose to 3.07 billion euros
($3.23 billion), surpassing the average analyst estimate of 2.84
billion euros posted on the company's website.
Sanofi said on Thursday that it still expects 2022 adjusted
earnings per share to grow at a low double-digit percentage.
Revenues of eczema and asthma treatment Dupixent jumped over
45% to 1.61 billion euros, beating an analyst consensus of 1.58
billion euros. ($1 = 0.9500 euros)
(Reporting by Ludwig Burger;
Editing by Sudip Kar-Gupta)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))